Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells.This expression pattern makes CD38 an interesting target for a targeted therapy aiming to deplete antibody-producing plasma cells.We present data suggesting